Rita P. Dalal

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Yung‐Jue Bang, Yoon‐Koo Kang, Daniel V.T. Catenacci et al. · Gastric Cancer · 2019 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang et al. · Journal of Clinical Oncology · 2017 · 173 citations

Medicine, Oncology, Pharmacotherapy +17

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Andrew X. Zhu, Richard S. Finn, Mary F. Mulcahy et al. · Clinical Cancer Research · 2013 · 165 citations · Full text

Medicine, Oncology, Pharmacology +17

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.

Yung‐Jue Bang, Kei Muro, Charles S. Fuchs et al. · Journal of Clinical Oncology · 2017 · 73 citations

Medicine, Oncology, Pharmacology +7

Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (<i>MET</i>^Amp/Ex14∆).

D. Ross Camidge, Filip Jankú, Alejandro Martínez‐Bueno et al. · Journal of Clinical Oncology · 2020 · 33 citations

Medicine, Oncology, Pharmacology +13